Literature DB >> 7774386

Management of the orbital contents in radical surgery for squamous cell carcinoma of the maxillary sinus.

X Wu1, P Tang, Y Qi.   

Abstract

We reviewed retrospectively 139 patients with squamous cell carcinoma of the maxillary sinus who were treated with planned combinations of preoperative radiotherapy and maxillectomy between 1958 and 1987. The 5-year survival rate of these patients was 30%. In 111 patients who had tumor invasion of the orbital floor 88 underwent radical surgery with orbital exenteration and 23 had their orbital contents preserved. If orbital exenteration was performed, the 5-year survival rate was 27.3% (24/88) and the rate of recurrence within the orbit was 12.5%. In patients with preservation of the orbital contents, the corresponding rates were 34.8% (8/23) and 8.6% respectively (P = 0.65). Histological study after maxillectomy with orbital exenteration showed that in 95% of 65 specimens (62/65) invasion of the orbit was limited. These tumors could be completely resected by total maxillectomy with limited removal of the periorbital tissues after preoperative radiotherapy. We conclude that after preoperative radiation, the eyeball could be safely preserved in most selected patients with maxillary sinus carcinoma invading the orbital floor.

Entities:  

Mesh:

Year:  1995        PMID: 7774386

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  3 in total

1.  To preserve or not to preserve the orbit in paranasal sinus neoplasms: a meta-analysis.

Authors:  Camilo Reyes; Eric Mason; C Arturo Solares; Carrie Bush; Ricardo Carrau
Journal:  J Neurol Surg B Skull Base       Date:  2014-11-06

2.  Sinonasal Malignancy and Orbital Exenteration Sparing Cancer Surgery.

Authors:  Camilo Reyes; Mihir Patel; C Arturo Solares
Journal:  J Neurol Surg B Skull Base       Date:  2020-08-20

Review 3.  Paranasal sinus cancer: caveats and controversies.

Authors:  John Waldron; Ian Witterick
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.